Steve Smith

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: a multicentre, open-label, phase 1 study

Jessica L. Davis, B. Tuch, A. Pappo, 2018 .

ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.

B. Tuch, Jing Ma, C. Mullighan, 2018, Blood.

Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)

B. Tuch, Alan Ho, N. Shukla, 2019, Clinical Trials.

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.

Jessica L. Davis, B. Tuch, A. Pappo, 2018, The Lancet. Oncology.

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.

B. Taylor, M. Berger, A. Drilon, 2017, Cancer discovery.

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations

P. Anderson, S. G. Raju, U. Gerdemann, 2020, JCO precision oncology.

Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer

B. Tuch, T. Kohno, J. Blake, 2019, JCO precision oncology.

Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)

J. Dipersio, I. Aldoss, M. Arellano, 2021, Blood.

Selective RET kinase inhibition for patients with RET-altered cancers

A. Drilon, B. Tuch, V. Velcheti, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

B. Tuch, J. Lee, A. Shaw, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.